4-[4-(4-Fluoro-phenyl)-thiazol-5-yl]-pyridine | 290357-29-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[4-(4-Fluoro-phenyl)-thiazol-5-yl]-pyridine
• 英文别名: 4-(4-fluorophenyl)-5-pyridin-4-yl-1,3-thiazole
• CAS: 290357-29-8
• 化学式: C₁₄H₉FN₂S
• 分子量: 256.303
• InChiKey: IYDSUKQRNVOVBV-UHFFFAOYSA-N

物化性质

• 沸点：
  370.7±32.0 °C(Predicted)
• 密度：
  1.280±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-[4-(4-Fluoro-phenyl)-thiazol-5-yl]-pyridine 在 ammonium hydroxide 、 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 17.0h， 生成 3,5-Difluoro-4-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-thiazol-2-yl]-pyridine-2,6-diamine
  参考文献：
  名称：

  SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38MAP kinase inhibitors

  摘要：

  2,6-Diamino-3,5-difluoropyridinyl substituted pyridinylimidazoles, -pyrroles, -oxazoles, -thiazoles and -triazoles have been identified as novel p38alpha inhibitors. Pyridinylimidazole 11 potently inhibited LPS-induced TNFalpha in mice, showed good efficacy in the established rat adjuvant (ED50: 10mg/kg po b.i.d.) and collagen induced arthritis (ED50: 5mg/kg po b.i.d.) with disease modifying properties based on histological analysis of the joints. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(02)00336-0
• 作为产物：
  描述：

  1-(4-氟苯基)-2-(4-吡啶基)乙酮 在 tetraphosphorus decasulfide 、 溴 、 碳酸氢钠 、 溶剂黄146 作用下， 反应 0.5h， 生成 4-[4-(4-Fluoro-phenyl)-thiazol-5-yl]-pyridine
  参考文献：
  名称：

  SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors

  摘要：

  The 4-hydroxypiyeridine substituent was found to confer high p38 selectivity devoid of COX-1 affinity, when attached to a series of pyridinyl substituted heterocycles. Pyridinyloxazole 11 showed a promising in vivo profile with bioavailability of 64% and ED50 in rat collagen induced arthritis of 10 mg/kg po bid. In contrast to pyridinylimidazoles such as SE 203580, 11 did not inhibit human cytochrome P450 isoenzymes. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00200-6

文献信息

• SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors
  作者：Laszlo Revesz、Franco E Di Padova、Thomas Buhl、Roland Feifel、Hermann Gram、Peter Hiestand、Ute Manning、Alfred G Zimmerlin

  DOI：10.1016/s0960-894x(00)00200-6

  日期：2000.6

  The 4-hydroxypiyeridine substituent was found to confer high p38 selectivity devoid of COX-1 affinity, when attached to a series of pyridinyl substituted heterocycles. Pyridinyloxazole 11 showed a promising in vivo profile with bioavailability of 64% and ED50 in rat collagen induced arthritis of 10 mg/kg po bid. In contrast to pyridinylimidazoles such as SE 203580, 11 did not inhibit human cytochrome P450 isoenzymes. (C) 2000 Elsevier Science Ltd. All rights reserved.
• SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38MAP kinase inhibitors
  作者：Laszlo Revesz、Franco E. Di Padova、Thomas Buhl、Roland Feifel、Hermann Gram、Peter Hiestand、Ute Manning、Romain Wolf、Alfred G. Zimmerlin

  DOI：10.1016/s0960-894x(02)00336-0

  日期：2002.8

  2,6-Diamino-3,5-difluoropyridinyl substituted pyridinylimidazoles, -pyrroles, -oxazoles, -thiazoles and -triazoles have been identified as novel p38alpha inhibitors. Pyridinylimidazole 11 potently inhibited LPS-induced TNFalpha in mice, showed good efficacy in the established rat adjuvant (ED50: 10mg/kg po b.i.d.) and collagen induced arthritis (ED50: 5mg/kg po b.i.d.) with disease modifying properties based on histological analysis of the joints. (C) 2002 Published by Elsevier Science Ltd.